wavelifesciences.com (WVE): Expected earnings per share growth for next year
Innovations in RNA editing and stereopure oligonucleotides are driving interest in Wave Life Sciences (WVE) assets. The history of forward earnings per share valuations visualizes this trend, where the value of -16.60 serves as the baseline indicator. The colossal scaling potential of the platform promises high margins, although success depends on the outcome of clinical trials and the stability of partnerships with pharma behemoths amid fierce competition.
WVE (Wave Life Sciences Ltd.): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization information:
- company total debt and liquidity indicators:
Total Debt to Capital Wave Life Sciences|WVE - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital wavelifesciences.com|WVE - Company Cumulative Debt|Debt to Book Capitalization Ratio Wave Pharma|WVE - Company Long-Term Indebtedness|Company Short-Term Debts Wave Life Sciences|Quick Ratio wavelifesciences.com
- net income and valuation ratios data:
WVE - Company Net Income|Expected Profit Wave Life Sciences|WVE - Business Payback Period|Projected Price to Earnings Wave Life Sciences Ltd|WVE - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Wave Life Sciences Ltd|WVE - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Wave Life Sciences|WVE - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth wavelifesciences.com|WVE - Earnings per share growth this year|Net earnings per share growth forecast for next year Wave Life Sciences
- revenue and sales details:
Fundamental company analysis:WVE, Wave Life Sciences Ltd.
The Wave Life Sciences (WVE) business model is based on a strategic partnership with a pharma behemoth that fully funds the development of RNA therapies. Within this structure, the earnings per share growth forecast trend measures the expected EPS dynamics, separating the fundamental development vector from market noise, which allows investors to assess the company's scaling potential through the prism of analysts' consensus estimates for the coming year.
Competing companies
TEM (Tempus) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year QGEN (Qiagen)|Earnings growth forecast for next year IONS|RGEN (Repligen) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year aviditybiosciences.com RNA|CRISPR (CRSP) - Expected net earnings per share growth next year|genedx.com - Earnings growth forecast for next year|Expected earnings per share trend next year RARE (ultragenyx.com)|BEAM: Earnings growth forecast for next year|Sarepta - Expected earnings per share trend next year|TWST (twistbioscience.com) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year TXG (10x Genomics Corp)|Earnings growth forecast for next year NTLA|Earnings growth forecast for next year Stoke Therapeutics, Inc. (STOK)|Net earnings per share growth forecast for next year BioLife BLFS|Consensus forecast of earnings per share growth for next year Maze Therapeutics (MAZE)|SION: Expected earnings per share growth for next year|Consensus forecast of earnings per share growth for next year Prime Medicine Bio PRME|TSHA: Earnings growth forecast for next year|Projected earnings per share growth rate for next year QURE|Expected earnings per share growth for next year MGTX|Projected earnings per share growth rate for next year RGNX (REGENXBIO)|Earnings growth forecast for next year SLDB|OCGN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Pacific Biosciences of California PACB|BNTC: Projected earnings per share growth rate for next year|DSGN - Net earnings per share growth forecast for next year|RCKT: Net earnings per share growth forecast for next year|FDMT - Projected earnings per share increase next year|Expected net earnings per share growth next year Lexeo Therapeutics Inc. (LXEO)|Net earnings per share growth forecast for next year Korro Bio Inc.|Editas Medicine (EDIT) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Silence Therapeutics Inc. (SLN)|PRQR: Net earnings per share change forecast for next year|Earnings growth forecast for next year CDXS (codexis.com)|SGMO: Projected earnings per share growth rate for next year|NAUT: Expected earnings per share growth for next year|Expected net earnings per share growth next year metagenomi.co|Precision BioSciences, Inc. (DTIL) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Generation Bio Corp (GBIO)|Expected earnings per share growth for next year BOLD|exicuretx.com (XCUR) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year IMNN (Celsion Corporation)|PHIO (Phio Pharmaceuticals Corp.) - Expected earnings per share trend next year|Earnings growth forecast for next year MBIO (Mustang Bio Corp)|Projected earnings per share increase next year RNAZ (TransCode Therapeutics)|BNGO - Net earnings per share growth forecast for next year|APDN: Net earnings per share growth forecast for next year|BLUE: Earnings growth forecast for next year|Expected earnings per share growth for next year ImmunoPrecise Antibodies|OMGA (Omega Therapeutics, Inc.) - Earnings growth forecast for next year|Singular Genomics (OMIC) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Regulus (RGLS)|SYRS (Syros Pharmaceuticals, Inc) - Expected earnings per share trend next year|Telesis Bio, Inc. - Expected earnings per share growth for next year|TCON: Projected earnings per share growth rate for next year|Unity Biotechnology Inc. - Earnings growth forecast for next year
